Whalen Wealth Management Inc. Buys Shares of 15,354 Hims & Hers Health, Inc. $HIMS

by · The Markets Daily

Whalen Wealth Management Inc. purchased a new stake in Hims & Hers Health, Inc. (NYSE:HIMS – Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 15,354 shares of the company’s stock, valued at approximately $871,000.

Several other large investors have also recently made changes to their positions in the stock. Virtus Advisers LLC acquired a new stake in shares of Hims & Hers Health during the second quarter worth about $26,000. Quaker Wealth Management LLC acquired a new stake in Hims & Hers Health during the 2nd quarter worth approximately $29,000. Bessemer Group Inc. boosted its position in Hims & Hers Health by 105.8% in the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after buying an additional 312 shares during the period. Geneos Wealth Management Inc. purchased a new position in Hims & Hers Health in the 1st quarter valued at approximately $30,000. Finally, Hilltop National Bank acquired a new position in shares of Hims & Hers Health in the third quarter worth $35,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. UBS Group set a $32.00 target price on Hims & Hers Health in a report on Tuesday, November 4th. BTIG Research reiterated a “buy” rating and issued a $85.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, November 4th. KeyCorp started coverage on Hims & Hers Health in a research report on Tuesday, October 21st. They set a “sector weight” rating for the company. Wall Street Zen cut shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, Bank of America lifted their price target on shares of Hims & Hers Health from $28.00 to $32.00 and gave the stock an “underperform” rating in a research note on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $45.50.

Get Our Latest Stock Report on Hims & Hers Health

Hims & Hers Health Trading Down 0.7%

HIMS opened at $34.74 on Friday. The firm has a market cap of $7.91 billion, a price-to-earnings ratio of 64.33, a price-to-earnings-growth ratio of 6.91 and a beta of 2.41. Hims & Hers Health, Inc. has a 52 week low of $23.97 and a 52 week high of $72.98. The business’s 50 day moving average is $42.22 and its two-hundred day moving average is $48.68. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last announced its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The business had revenue of $598.98 million for the quarter, compared to analysts’ expectations of $578.99 million. During the same quarter last year, the business posted $0.32 earnings per share. The business’s revenue was up 49.2% on a year-over-year basis. On average, research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health declared that its Board of Directors has authorized a share buyback program on Monday, November 17th that allows the company to buyback $250.00 million in outstanding shares. This buyback authorization allows the company to buy up to 3% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Insider Activity

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 10,021 shares of the company’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $367,870.91. Following the completion of the transaction, the insider owned 169,940 shares in the company, valued at approximately $6,238,497.40. This represents a 5.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Irene Becklund sold 8,411 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $308,767.81. Following the completion of the sale, the insider owned 2,126 shares of the company’s stock, valued at approximately $78,045.46. The trade was a 79.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 233,429 shares of company stock worth $11,769,372 over the last quarter. 13.71% of the stock is owned by insiders.

Hims & Hers Health Company Profile

(Free Report)

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Featured Articles

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS – Free Report).